Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
The Pharmacist’s Guide to Patient Identification, Testing, and Antiviral Use.
Choose from the criteria below to find an activity that fits you best.
The COVID-19 pandemic has understandably resulted in the assessment of numerous medical practices that have the potential to result in viral transmission. This activity addresses the variables to evaluate for aerosol-generating procedures, including a look at the mechanism of respiratory viral transmission, national and international definitions and discusses data related to COVID-19 and nebulization.
The target audience for this activity includes pharmacists, nurses and physicians.
At the completion of this activity, the participant will be able to:
Antonio Anzueto, MD
Professor of Medicine, Pulmonary/Critical Care
University of Texas Health, San Antonio
Section Chief, Pulmonary
South Texas Veterans Health Care System
San Antonio, Texas
J. Andrew Woods, Pharm.D., BCPS
Associate Professor of Pharmacy
Wingate University School of Pharmacy
Clinical Team Lead, Internal Medicine
Atrium Health - Carolinas Medical Center Main
Department of Pharmacy
Charlotte, North Carolina
Release Date: December 3, 2020
Expiration Date: December 30, 2021
ACPE Credit Designation (Pharmacist CE)
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as
a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-20-532-H01-P
has been assigned to this home study knowledge-based activity. This activity is approved
for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity
is provided at no cost to participants. Completion of an evaluation and post-test
with a score of 70% or higher is required to receive CE credit. Proof of completion
will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented
by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is
jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing
Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category
1 Credit™. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity
is 1.0 contact hour.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty and planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Dr. Anzueto has received consulting fees from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, and Mylan/Theravance Biopharma.
Dr. Woods has received fees from Boehringer Ingelheim for non-CME/CE services.
Richard K. Lewis, PharmD, MBA has no relevant conflicts of interest to report.
Maureen George, PhD, has disclosed that she has received consulting fees from AstraZeneca, Sanofi/Regeneron and Teva and fees for Non-CME/CE services from Genentech.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from Theravance Biopharma.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.